Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03997123 · ClinicalTrials.gov registry record · Phase 3

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

A Phase 3 study of Triple Negative Breast Neoplasms, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
923
Enrollment target
20
Study locations

NCT03997123 is a Phase 3 study of Triple Negative Breast Neoplasms that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 923 participants, above the 571-participant average among 10 other Triple Negative Breast Neoplasms trials with a reported enrollment target (62% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03997123, a Phase 3 study of Triple Negative Breast Neoplasms, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
923 participants
Enrollment target
20
Study locations

Study Summary

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)

Conditions Studied

Triple Negative Breast Neoplasms

Interventions

  • DRUG Placebo
  • DRUG Paclitaxel
  • DRUG Capivasertib

Study Locations (20)

Florida

  • Research Site - Fort Myers
  • Research Site - Miami
  • Research Site - St. Petersburg
  • Research Site - Tampa

Pennsylvania

  • Research Site - Harrisburg
  • Research Site - Philadelphia
  • Research Site - Pittsburgh

Texas

  • Research Site - Austin
  • Research Site - Fort Worth
  • Research Site - Houston

California

  • Research Site - Whittier
  • Research Site - Whittier

Ohio

  • Research Site - Cincinnati
  • Research Site - Columbus

Illinois

  • Research Site - Chicago

Kansas

  • Research Site - Westwood

Maryland

  • Research Site - Silver Spring

Trial Details

FieldValue
Enrollment Target 923 participants
Start Date 2019-06-25
Est. Completion 2026-03-16
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03997123

The ClinicalTrials.gov registry entry for NCT03997123 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 923 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 571-participant average among 10 other Triple Negative Breast Neoplasms trials with a reported enrollment target (62% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Triple Negative Breast Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT03997123 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Pennsylvania, Texas.

Frequently Asked Questions

What is clinical trial NCT03997123 about?

NCT03997123 is a clinical study titled "Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC". Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)

What is the current status of trial NCT03997123?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 923 participants. The study started on 2019-06-25. Estimated completion is 2026-03-16.

What conditions does trial NCT03997123 study?

This clinical trial studies the following conditions: Triple Negative Breast Neoplasms.

What interventions are being tested in trial NCT03997123?

The interventions under investigation include: Placebo (DRUG), Paclitaxel (DRUG), Capivasertib (DRUG).

Who is sponsoring clinical trial NCT03997123?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03997123 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Triple Negative Breast Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Triple Negative Breast Neoplasms

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.